Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer

PURPOSE: In 2002, pegfilgrastim was approved by the US Food and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR) –negative tumors, were reported. We examined first-cycle colony-stimulating factor use (FC-CSF) before and after 2002 an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Hershman, Dawn L., Wilde, Elizabeth T., Wright, Jason D., Buono, Donna L., Kalinsky, Kevin, Malin, Jennifer L., Neugut, Alfred I.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2012
Pynciau:
Original Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3295569/
https://ncbi.nlm.nih.gov/pubmed/22312106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.7499
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg